MTVA · XBRL financial data

MetaVia financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MTVA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	—	—	—	8,074	4,517	4,058*	2,327	2,320	1,914	241*	2,101	3,478
General and administrative	1,601	1,802*	1,977	2,010	1,742	1,527*	1,559	1,981	1,561	1,805*	1,924	1,907
Total operating expenses	—	—	—	10,084	6,259	5,585*	3,886	4,301	3,475	2,046*	4,025	5,385
Operating income (loss)	(3,893)	(5,667)*	(6,881)	(10,084)	(6,259)	(5,585)*	(3,886)	(4,301)	(3,475)	(2,046)*	(4,025)	(5,385)
Other income (expense)	75	353*	167	31	607	412*	215	306	98	116*	202	69
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0	0	0*	0	0
Net income (loss)	(3,818)	(5,314)*	(6,714)	(10,053)	(5,652)	(5,173)*	(3,671)	(3,995)	(3,377)	(1,930)*	(3,823)	(5,316)
Earnings per share, basic‡ USD per share	(1,950.71)	—	(14.51)	(20.33)	(6.04)	—	(3.96)	(2.86)	(1.54)	—	(0.79)	(0.90)
Earnings per share, diluted‡ USD per share	(1,950.71)	—	(14.51)	(20.33)	(6.04)	—	(3.96)	(2.86)	(1.54)	—	(0.79)	(0.90)
Weighted average shares, basic‡ thousands of shares	2	—	463	494	929	—	934	1,391	2,222	—	4,860	5,932
Weighted average shares, diluted‡ thousands of shares	2	—	463	494	929	—	934	1,391	2,222	—	4,860	5,932

‡ Per-share figures and share counts are adjusted for the 1-for-7.692307692307692 stock split (December 2023); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-10.989010989010989 stock split (December 2025); filings made before it reported them unadjusted.
† Share count changed about 32x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (MTVA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	25,837	22,435	15,988	27,934	21,669	16,017	11,190	17,589	14,277	10,278	13,731	12,634
Prepaid and other current assets	—	77	776	583	266	55	771	726	369	597	431	433
Total current assets	26,145	22,512	16,764	28,517	21,935	16,072	11,961	18,315	14,646	10,875	14,162	13,067
Property and equipment, net	41	46	47	44	39	34	30	27	22	17	12	8
Right-of-use asset	218	202	186	169	151	133	115	96	76	210	193	175
Total assets	26,425	22,781	17,018	28,751	22,146	16,260	12,127	18,459	14,765	11,123	14,388	13,271
Accounts payable	1,981	821	2,079	2,632	1,017	3,879	3,054	2,875	2,599	1,060	1,007	921
Accrued liabilities	1,614	4,414	3,948	—	—	—	—	—	—	—	—	—
Total current liabilities	4,722	5,960	6,825	9,711	9,114	8,271	7,710	8,820	8,434	5,648	5,192	6,346
Lease liability, non-current	153	136	117	98	79	58	37	15	—	142	123	103
Total liabilities	4,875	6,096	6,942	9,809	9,193	8,329	7,747	8,835	8,434	5,790	5,315	6,449
Accumulated deficit	(102,951)	(108,265)	(114,979)	(125,032)	(130,684)	(135,857)	(139,528)	(143,523)	(146,900)	(148,830)	(152,653)	(157,969)
Total stockholders' equity	21,550	16,685	10,076	18,942	12,953	7,931	4,380	9,624	6,331	5,333	9,073	6,822
Total liabilities and equity	26,425	22,781	17,018	28,751	22,146	16,260	12,127	18,459	14,765	11,123	14,388	13,271
Common shares outstanding (cover page)‡ thousands of shares	2	58	446	770	784	788	1,780	2,202	2,204	5,091	5,164	6,588

‡ Per-share figures and share counts are adjusted for the 1-for-7.692307692307692 stock split (December 2023); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-10.989010989010989 stock split (December 2025); filings made before it reported them unadjusted.
† Share count changed about 32x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (MTVA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(3,818)	(5,314)*	(6,714)	(10,053)	(5,652)	(5,173)*	(3,671)	(3,995)	(3,377)	(1,930)*	(3,823)	(5,316)
Stock-based compensation	172*	100*	105	134*	139*	160*	132	111*	97*	71*	100	130*
Net cash from operating activities	(2,814)*	(3,393)*	(6,442)	(7,251)*	(5,589)*	(5,428)*	(4,815)	(3,071)*	(2,955)*	(4,860)*	(4,258)	(3,762)*
Purchases of property and equipment	37*	9*	5	3*	0*	0*	—	—	0*	0*	—	—
Net cash from investing activities	(37)*	(9)*	(5)	(3)*	0*	0*	—	—	0*	0*	—	—
Proceeds from issuing equity	—	—	0	19,998*	0*	—	—	—	—	—	—	—
Net cash from financing activities	0*	0*	—	—	(676)*	(224)*	(12)	9,472*	(357)*	861*	7,711	2,665*

† Share count changed about 32x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
MetaVia	12,634	not reported	(3,762)*	6.6M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Oragenics	3,864	not reported	(2,187)*	4.5M	1.8 quarters	Q2 FY26 10-QJun 30, 2026
Inhibitor Therapeutics	516	not reported	(775)*	173.8M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
PTC Therapeutics	508,894	357,807	(25,311)*	83.5M	—	Q3 FY26 10-QSep 30, 2026
Propanc Biopharma	832	not reported	(1,602)*	6.3M	0.5 quarters	Q4 FY26 10-KJun 30, 2026
Integrated Biopharma	4,471	not reported	(1,194)*	31.1M	3.7 quarters	Q4 FY26 10-KJun 30, 2026
Cannapharmarx	0.6	276	(127)*	708.7M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Enveric Biosciences	8,296	not reported	(2,445)*	4.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Polomar Health Services	179	1,529	121*	28.4M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.